« Summer Funny - BrainFreeze Video |
Main
| UC Merced Opens Today »
September 1, 2005
Treating Pain - Special Neurotech Insights Issue
Posted by Zack Lynch
We all feel pain. Some 87 million Americans and over 290 million individuals worldwide suffer from some form of chronic pain. Sales of therapeutics for pain management reached over $20 billion last year, up 11%.
To learn more about the past, present and future of the pain management market then don't miss the latest issue of Neurotech Insights - the neurotechnology investment newsletter. Included in this issue:
-Next Generation Pain Treatments (in-depth analysis with latest clinical trials)
-Interview with Pain Therapeutics CEO, Remi Barbier
-Discussion of neurostimulation treatments for pain management
-Market analysis of public companies (RNVS, CEPH, MDT, DOVP, NTII, SHPGY)
-Deals, alliances and financings
-Neurotech Index performance (companies treating neurological diseases)
If you are an investor, corporate executive, researcher, or someone who suffers from chronic pain I recommend picking up the latest copy of Neurotech Insights - the biweekly neurotechnology investment newsletter.
Comments (1)
+ TrackBacks (0) | Category: Neurotech Industry
- RELATED ENTRIES
- › Neurotech 2010: Translational Researchers Highlight Innovation
- › The Neuro Revolution in China Progressing
- › Speakers for Neurotech 2010 - Boston, May 19-20
- › Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow
- › McGovern Institue for Brain Research at MIT Goes Web 2.0
- › The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
- › Neuropharma FDA Approvals Down in 2009
- › Tel Aviv Neurotech Cluster Thrives
Zack Lynch is author of 
1. bill on September 6, 2005 2:22 PM writes...
I would think if you're going to devote an entire blog column to a magazine issue that you would have the magazine (or at least 1 or 2 articles) freely available to peruse. In light of that, the column appears to provide nothing more than an advertisement to purchase (for $50) one of your products. I suppose it's your blog though.
Permalink to Comment